Cancer Research AACR Conference on Molecular Diagnostics Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
[Cancer Research 59, 4237-4241, September 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Allen, J. D.
Right arrow Articles by Schinkel, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Allen, J. D.
Right arrow Articles by Schinkel, A. H.
[Cancer Research 59, 4237-4241, September 1, 1999]
© 1999 American Association for Cancer Research

Advances in Brief

The Mouse Bcrp1/Mxr/Abcp Gene

Amplification and Overexpression in Cell Lines Selected for Resistance to Topotecan, Mitoxantrone, or Doxorubicin1

John D. Allen, Remco F. Brinkhuis, Jan Wijnholds and Alfred H. Schinkel2

Divisions of Experimental Therapy [J. D. A., R. F. B., A. H. S.] and Molecular Biology [J. W.], The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
Mouse fibroblast cell lines lacking functional Mdr1a, Mdr1b, and Mrp1 genes were selected for resistance to topotecan, mitoxantrone, or doxorubicin. Each of the resulting drug-resistant lines showed marked gene amplification of Bcrp1, the mouse homologue of the human ATP-binding cassette transporter gene BCRP/MXR/ABCP, and greatly elevated expression of Bcrp1 mRNA. All three of the resistant cell lines were highly cross-resistant to topotecan and mitoxantrone and, to a variable extent, doxorubicin. All showed greatly reduced cellular accumulation and greatly increased efflux of mitoxantrone that was dependent on cellular ATP and efficiently reversed by the compound GF120918. The mouse Bcrp1 cDNA encodes a 657-amino-acid protein with 81% identity (86% similarity) to the human breast cancer resistance protein (BCRP) and a virtually superimposable hydrophobicity profile. Our data argue strongly that mouse Bcrp1 is functionally comparable with human BCRP, conferring multidrug resistance to topotecan, mitoxantrone, doxorubicin, and related compounds. Mouse models and cell lines should, therefore, be highly informative in understanding the clinical, pharmacological, and physiological roles of BCRP.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
Several sources of MDR3 have been identified and well studied. They include elevated levels of P-gp or the MDR protein MRP1, both members of the ABC transmembrane protein family (1, 2, 3, 4) . The proteins are efflux pumps situated in the plasma membrane, with broad substrate specificities including several clinically important antineoplastic drugs. Despite extensive knowledge of their activity in vitro and evidence of their involvement in MDR in certain types of tumors, it is still unclear what mechanisms contribute most to MDR in many clinical tumors. It is very possible that as yet unidentified or poorly understood mechanisms will turn out to be as important in clinical practice as P-gp and MRP1. The recently identified ABC gene BCRP/MXR/ABCP is a candidate for such a mechanism, inasmuch as its expression in transfected cell lines confers resistance to doxorubicin, mitoxantrone, and related drugs (5, 6, 7) . Cross-resistance to mitoxantrone and doxorubicin that is associated with reduced drug accumulation but not elevated P-gp or MRP1 has been reported previously for a number of drug-selected cell lines (8, 9, 10, 11) . In some of these lines cross-resistance to topotecan was also noted (12 , 13) . Drug resistance in several of these lines has now been attributed to elevated expression of BCRP (5 , 7 , 14 , 15) .

Mouse cell lines lacking functional Mdr1a and Mdr1b (encoding mouse P-gps), and Mrp1 genes constitute a potentially fertile resource for identifying new mechanisms of drug resistance. Such lines are markedly more sensitive than equivalent wild-type lines are to P-gp and MRP1 substrate drugs, including doxorubicin, paclitaxel, topotecan, and vincristine.4 Selection of these lines for resistance to antineoplastic drugs may, therefore, invoke resistance mechanisms normally masked or overshadowed by the presence of P-gp or Mrp1. Indeed, we report here that selection with topotecan, mitoxantrone, or doxorubicin readily resulted in overexpression of the mouse Bcrp1 gene.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Cell Lines.
Adherent, spontaneously immortalized embryo (MEF3.8) and ear (KOT52) fibroblast cell lines were derived by 3T3-like procedures (16) from Mdr1a/b-/-Mrp1-/- mice, obtained by crossing Mdr1a-/-Mdr1b-/- (17) and Mrp1-/- (18) knockout mice. Cells were grown in complete medium, i.e., DMEM supplemented with 10% FCS, and passaged by trypsinization. Drug-resistant sublines were selected by continuous exposure to topotecan, mitoxantrone, or doxorubicin, with repeated two-fold increments in drug concentration over a period of 4–8 months, corresponding to 20–40 passages.

Drug Resistance Assays.
Growth inhibition (IC50) assays were performed by seeding 250 or 500 cells per well in 96-well plates in complete medium and applying drugs in a dilution series, each concentration in quadruplicate wells. After 4–4.5 days, when unselected wells were still subconfluent, cells were lysed in situ, nucleic acids were stained with a proprietary dye (Cyquant, Molecular Probes, Eugene, OR), and quantified by UV fluorescence (485 nm excitation, 530 nm emission). All such assays were performed three times.

Mitoxantrone Accumulation and Efflux Assays.
Relative cellular accumulation of mitoxantrone was determined by flow cytometry using excitation at 633 nm and a 661 nm band-pass filter to detect emission. All of the assays were conducted at 37°C with 105 (subconfluent) cells per well in 12-well plates, seeded in complete medium without drug the night before. Mitoxantrone was added for timed intervals in fresh, prewarmed, complete medium containing 5% FCS. Accumulation or efflux was arrested by prompt cooling on ice, and the cells were maintained at 0°C during all of the subsequent steps, including trypsinizing. Where indicated (see "Results"), mitoxantrone accumulations were done in the presence of 2 µM GF120918; pilot experiments indicated that this concentration gave >95% maximal effect. Cells were preincubated with GF120918 for 30–60 min before adding mitoxantrone. Accumulation under ATP-depleting conditions was performed for 2 h in glucose-free, pyruvate-free DMEM containing 5% dialyzed FCS, plus 10 mM sodium azide to inhibit oxidative phosphorylation, as described previously (19) . Mitoxantrone efflux was assayed after accumulation under ATP-depleting conditions: the medium and drug were removed by aspiration, wells were washed quickly with complete medium at room temperature, and the cells were then incubated with prewarmed complete medium at 37°C for timed intervals prior to harvesting. Assays were performed at least twice, each time with triplicate wells.

Bcrp Cloning and Sequencing.
Mouse Bcrp1 cDNAs were amplified by PCR with primers based on mouse EST sequences homologous to the 5' and 3' ends of human BCRP, with XbaI linkers added: 5'-GAG TGA GAT CTA GAA GGC ATA AAT CCT AAA GAT GTC TTC C and 3'-AAG GTA AGT CTA GAG GAG TAC AAT TAA TAG TCC GTT AAA GG. The PCR was performed with Pfu polymerase, Stratagene, La Jolla, CA) on oligo-dT primed first-strand cDNA from liver, yielding a product of 2.0 kb, as expected by analogy with the human BCRP sequence. cDNA clones from two independent amplifications were completely sequenced on both strands.5 Minor discrepancies between the two clones and with existing mouse ESTs were resolved by sequencing relevant portions of a Bcrp1 genomic clone derived from the 129/Ola mouse strain. A slightly shorter PCR product covering only the Bcrp1 coding sequence was used for probing blots (nucleotides 19 through 1977 in the GenBank sequence5 ). A short probe for Bcrp2 covering the 3' coding region was obtained similarly by PCR based on the sequence of mouse EST AA277174.


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
Selection of Resistant Lines and Analysis of Cross-Resistance.
Cell lines nullizygous for Mdr1a, Mdr1b and Mrp1 were selected for resistance to topotecan, mitoxantrone or doxorubicin (see "Materials and Methods" for details). The embryo fibroblast line MEF3.8 yielded the topotecan-resistant subline T6400 and the mitoxantrone-resistant subline M32. The ear fibroblast line KOT52 yielded a doxorubicin-resistant subline, D320. Compared with their parental lines, the sublines were each more than 100-fold resistant to the selecting drug but remained sensitive to paclitaxel, vincristine and cisplatin (Table 1)Citation . The T6400, M32 and D320 lines were all highly cross-resistant to topotecan and mitoxantrone. The T6400 and M32 lines also showed some cross-resistance to anthracyclines and bisantrene (a compound structurally related to mitoxantrone) but at a much lower level than the doxorubicin-selected D320 line. The D320 line was also much more resistant to etoposide.


View this table:
[in this window]
[in a new window]
  		Table 1 Cross-resistance profile of Mdr1a/b-/- Mrpl-/- fibroblast lines selected for resistance to mitoxantrone, topotecan, or doxorubicin

 
Reduced Drug Accumulation and Increased Efflux.
Doxorubicin and mitoxantrone interfere with topoisomerase II activity, whereas topotecan acts on a different target, topoisomerase I. Cross-resistance to both types of drugs could be explained most easily by reduced cellular drug accumulation, which can be readily measured for mitoxantrone by flow cytometry. Indeed, as a function of either time (Fig. 1A)Citation or drug concentration (Fig. 1B)Citation , mitoxantrone accumulation was greatly reduced in all three of the resistant sublines compared with the sensitive parental lines. The accumulation deficits could be largely reversed by performing the assays under conditions that deplete cellular ATP (Fig. 1C)Citation , which indicates that they are mediated by an ATP-dependent mechanism. The accumulation deficits were similarly reversed in the presence of GF120918, a known P-gp inhibitor (19) also reported to inhibit human BCRP (20) . Confocal scanning microscopy revealed no qualitative differences in the subcellular localization of mitoxantrone in resistant versus sensitive cells (data not shown), implying that the mechanism responsible for reduced accumulation operates at the plasma membrane.



View larger version (27K):
[in this window]
[in a new window]
  		Fig. 1. Mitoxantrone accumulation as measured by flow cytometry in resistant cell lines versus sensitive parental lines: A, as a function of time; B, as a function of mitoxantrone concentration (accumulation for 80 min); and C, under ATP-depleting conditions (glucose-free medium plus sodium azide; see "Materials and Methods" for details) or in the presence of 2 µM GF120918 for 2 h. D, mitoxantrone efflux from resistant versus sensitive lines under normal conditions after loading under ATP-depleted conditions. Unless otherwise indicated, mitoxantrone was applied at a concentration of 20 µM. All of the assays were performed in triplicate, at least twice. Error bars, the SDs of mean values from individual experiments.

 
Comparisons of mitoxantrone efflux rates under normal cell culture conditions were forestalled by the large differences in drug accumulation; it was not feasible to load the drug-resistant sublines to intracellular mitoxantrone levels similar to those obtained in the drug-sensitive parental lines, even using 200-fold greater concentrations of applied mitoxantrone. Nevertheless, similar mitoxantrone loadings were possible under ATP-depleting conditions, and efflux could be monitored after returning the loaded cells to normal conditions. The results (Fig. 1D)Citation show dramatically increased mitoxantrone efflux from the resistant sublines compared with the sensitive parental lines. Because recovery from ATP-depleted conditions is probably not immediate, the efflux curves likely underestimate the normal mitoxantrone efflux activity in these lines.

Cloning and Sequencing of Mouse Bcrp1.
The cross-resistance patterns and the ATP-dependent changes in mitoxantrone accumulation and efflux and their inhibition by GF120918 suggested the possibility of up-regulation of a mouse homologue of BCRP in one or more of the resistant lines. We, therefore, cloned and analyzed a mouse cDNA, Bcrp1, closely homologous to human BCRP. cDNAs containing the full Bcrp1 coding sequence were obtained by high-fidelity PCR based on existing mouse EST sequences homologous to the 5' and 3' ends of human BCRP. The cDNA sequence5 contains an extended open reading frame starting four codons downstream of an in-frame stop codon. This encodes an ABC transporter "half molecule" of 657 amino acids corresponding closely in sequence and structure to human BCRP (Fig. 2)Citation . The mouse Bcrp1 and human BCRP amino acid sequences are 81% identical and 86% homologous. Conservation is, as expected, very high in the ATP-binding cassette. The level of conservation between the mouse and human polypeptides is comparable with that between human MDR1 and mouse Mdr1a (87% identity) or Mdr1b (81% identity). Hydrophobicity plots of mouse Bcrp1 and human BCRP are almost identical (Fig. 2)Citation , increasing confidence in the assignment of six putative transmembrane domains (5 , 6) . However, the locations of charged amino acids in the mouse sequence merited small shifts in the positions assigned to some of the transmembrane domains relative to those proposed for human BCRP. Four potential sites for N-linked glycosylation are apparent; the first two lie in what is likely to be the cytosolic part of the protein, whereas the latter two are closely spaced in the loop between the fifth and sixth putative transmembrane domains and are, thus, probably extracellular (only one is conserved in human BCRP).



View larger version (31K):
[in this window]
[in a new window]
  		Fig. 2. The mouse Bcrp1 polypeptide sequence and superimposed hydrophobicity plots of the mouse Bcrp1 and human BCRP polypeptides. Amino acids that differ in the human BCRP sequence (taken from GenBank, accession AF098951) are shown below their mouse counterparts. Colons indicate conservative substitutions, and dashes are alignment gaps. Putative features are marked: overscore, transmembrane segments; double overscore, Walker A and B motifs; box, potential N-linked glycosylation sites, although the first two of these are presumed to lie within the cytosolic portion of the protein. The hydrophobicity plot was determined by the Kyte-Doolittle method using a window-length of 17 amino acids; bars, putative transmembrane regions.

 
Bcrp1 Overexpression and Amplification in Resistant Cell Lines.
On Northern blots (Fig. 3A)Citation , the Bcrp1 coding sequence probe identified either one or two bands at about 2.6 kb in the resistant sublines and mouse liver, similar to observations for the human BCRP mRNA (5, 6, 7) . Bcrp1 mRNA was expressed in each of the three resistant cell lines at roughly similar levels. The mRNA was not detectable in the parent cell lines at this sensitivity; this implies an increase in expression of more than 10-fold. The significance of the two transcripts is not known, but in humans, they may stem from alternate polyadenylation sites (7) or differences at the 5' end of the mRNA (6) . The elevated Bcrp1 expression was associated with heavy amplification of the gene locus, in each case greater than 20-fold compared with the drug-sensitive parent lines (Fig. 3B)Citation , as has been observed in several drug-resistant human cell lines overexpressing BCRP (7 , 15) .



View larger version (46K):
[in this window]
[in a new window]
  		Fig. 3. A, Northern analysis of Bcrp1 mRNA expression in the drug-resistant cell lines versus their sensitive parental lines. A 1.95-kb Bcrp1 coding sequence probe was used. A mouse liver sample was included for comparison of expression level, but its migration in the gel was slightly retarded by salt in the sample. Each lane on the blot contained 5 µg total RNA. Subsequent hybridization of the blot with an 18S-rRNA probe provided a loading control. B, Southern analysis of Bcrp1 copy number in the same panel of cell lines, using 5 µg of KpnI-digested genomic DNA per lane. Hybridization of the blot with a glyceraldehyde phosphate dehydrogenase (gapdh) probe provided an independent loading control, indicating that the D320 lane was substantially underloaded. The quantitation of Bcrp1 amplification reported in the text included normalization for the gapdh signal.

 
Two mouse ESTs for a sequence related to human BCRP but distinct from Bcrp1 were also identified (AA277174 and AI463023). We tentatively denote this sequence Bcrp2. One might speculate that the molecule encoded by Bcrp2 represents a partner for Bcrp1 in heterodimers. However, its expression, already very low in the MEF3.8 and KOT52 parental lines as determined by RNase protection, was not elevated in the drug-resistant sublines (data not shown).


   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
Our data show that the mouse Bcrp1 gene is readily amplified and overexpressed in cell lines made resistant to three different drugs—topotecan, mitoxantrone, and doxorubicin. The resistant sublines display greatly reduced mitoxantrone accumulation via an ATP-dependent efflux mechanism. All of the lines are characterized by cross-resistance to topotecan and mitoxantrone, and also to doxorubicin, albeit to a lesser extent in the M32 and T6400 lines than in the doxorubicin-selected D320 line. The evidence at hand strongly favors the interpretation that Bcrp1 overexpression is responsible for much of this pattern of resistance. Cross-resistance to mitoxantrone and doxorubicin in drug-selected human cell lines has, in several cases, now been attributed to BCRP overexpression (5 , 7 , 15) . Although concomitant cross-resistance to topotecan has been observed in a few cases (12 , 13) , we have now shown that Bcrp1 expression is also readily elevated by topotecan selection per se. The same could occur in human tumors, some of which are extensively treated with topotecan in the clinic.

Mouse Bcrp1, thus, appears functionally comparable with the human BCRP as a multidrug transporter. Functional homology is also suggested by the close structural similarities between the mouse and human polypeptides. Mouse models, therefore, will likely be appropriate and valuable for investigating the biochemistry and physiological functions of the BCRP/Bcrp1 protein, and its significance for drug pharmacokinetics and drug-resistance in tumors. We are currently developing such models.

The availability of effective inhibitors of Bcrp1 will be invaluable to such studies. It is of great interest that GF120918 turns out to be an effective inhibitor of both human BCRP (20) and mouse Bcrp1. GF120918 has very low toxicity, and it has already been administered at considerable doses to both animals (19) and patients6 to inhibit P-gp activity. Pilot experiments indicate that GF120918 is nearly as efficient at inhibiting murine Bcrp1. Thus, if BCRP contributes to clinical drug resistance, GF120918 may well be attractive as a dual-action reversal/sensitizing agent, coadministered to enhance the response to chemotherapy.

The doxorubicin-selected D320 subline showed considerably greater resistance to anthracyclines bisantrene and etoposide than the other two resistant sublines (Table 1)Citation , whereas the Bcrp1 expression level did not differ markedly (Fig. 3)Citation . Evidently, additional changes occurred in this subline. Each of the above drugs affects topoisomerase II activity; therefore, it may be that topoisomerase II function is altered in the D320 line. Alternatively, the function of Bcrp1 may be changed, for instance, by a mutation that affects substrate specificity. Because Bcrp1 is an ABC transporter half molecule, it may form homodimers or heterodimers. In the latter case, although speculative, different partner molecules could confer different substrate specificities on the dimer. These possibilities are now under investigation.

Finally, we note that the ranges of drugs transported by BCRP and P-gp overlap. If BCRP does prove significant in clinical drug resistance, this significance can only increase when drug-resistance reversal agents that inhibit P-gp are used in chemotherapy. Indeed, clinical use of inhibitors for any of the drug transporters will likely bring new drug resistance mechanisms to the fore. The value of anticipating such clinical developments in the laboratory is obvious. Our results illustrate the utility of cell lines nullizygous for known MDR genes for identification and characterization of such potential new resistance mechanisms.


   ACKNOWLEDGMENTS
 
We thank Drs. P. Borst, J. H. M. Schellens, M. Maliepaard, and J. W. Smit for valuable discussions and comments on the manuscript; E. Wagenaar for mouse work; and J. W. Jonker for assistance with RNase protection assays. GF120918 was kindly provided by GlaxoWellcome, Greenford, England, with the help of Drs. J. H. M. Schellens and O. van Tellingen.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by Dutch Cancer Society Grant NKI 97-1433. Back

2 To whom requests for reprints should be addressed, at Division of Experimental Therapy, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands. Back

3 The abbreviations used are: MDR, multidrug resistance; MRP, MDR-associated protein; ABC, ATP-binding cassette; BCRP, breast cancer resistance protein; P-gp, P-glycoprotein; EST, expressed sequence tag. Back

4 J. D. Allen, R. F. Brinkhuis, J. Wijnholds, P. Borst, and A. H. Schinkel. The contribution of multidrug transporters to basal drug resistance of mouse cell lines; manuscript in preparation. Back

5 The Bcrp1 sequence was deposited in GenBank under accession number AF140218. Back

6 J. H. M. Schellens, personal communication. Back

Received 6/16/99. Accepted 7/15/99.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Juliano R. L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 455: 152-162, 1976.[Medline]
  2. Chen C. J., Chin J. E., Ueda K., Clark D. P., Pastan I., Gottesman M. M., Roninson I. B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell, 47: 381-389, 1986.[Medline]
  3. Gros P., Croop J., Housman D. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell, 47: 371-380, 1986.[Medline]
  4. Cole S. P., Bhardwaj G., Gerlach J. H., Mackie J. E., Grant C. E., Almquist K. C., Stewart A. J., Kurz E. U., Duncan A. M., Deeley R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Washington DC), 258: 1650-1654, 1992.[Abstract/Free Full Text]
  5. Doyle L. A., Yang W., Abruzzo L. V., Krogmann T., Gao Y., Rishi A. K., Ross D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA, 95: 15665-15670, 1998.[Abstract/Free Full Text]
  6. Allikmets R., Schriml L. M., Hutchinson A., Romano-Spica V., Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res., 58: 5337-5339, 1998.[Abstract/Free Full Text]
  7. Miyake K., Mickley L., Litman T., Zhan Z., Robey R., Cristensen B., Brangi M., Greenberger L., Dean M., Fojo T., Bates S. E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res., 59: 8-13, 1999.[Abstract/Free Full Text]
  8. Chen Y. N., Mickley L. A., Schwartz A. M., Acton E. M., Hwang J. L., Fojo A. T. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J. Biol. Chem., 265: 10073-10080, 1990.[Abstract/Free Full Text]
  9. Dietel M., Arps H., Lage H., Niendorf A. Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85–257. Cancer Res., 50: 6100-6106, 1990.[Abstract/Free Full Text]
  10. Futscher B. W., Abbaszadegan M. R., Domann F., Dalton W. S. Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. Biochem. Pharmacol., 47: 1601-1606, 1994.[Medline]
  11. Lee J. S., Scala S., Matsumoto Y., Dickstein B., Robey R., Zhan Z., Altenberg G., Bates S. E. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J. Cell. Biochem., 65: 513-526, 1997.[Medline]
  12. Yang C. J., Horton J. K., Cowan K. H., Schneider E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res., 55: 4004-4009, 1995.[Abstract/Free Full Text]
  13. Rabindran S. K., He H., Singh M., Brown E., Collins K. I., Annable T., Greenberger L. M. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res., 58: 5850-5858, 1998.[Abstract/Free Full Text]
  14. Hazlehurst L. A., Foley N. E., Gleason-Guzman M. C., Hacker M. P., Cress A. E., Greenberger L. W., De Jong M. C., Dalton W. S. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res., 59: 1021-1028, 1999.[Abstract/Free Full Text]
  15. Ross D. D., Yang W., Abruzzo L. V., Dalton W. S., Schneider E., Lage H., Dietel M., Greenberger L., Cole S. P., Doyle L. A. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl. Cancer Inst., 91: 429-433, 1999.[Abstract/Free Full Text]
  16. Todaro G. J., Green H. Quantitative studies of the growth of mouse embryo cells in culture and their development into established cell lines. J. Cell Biol., 17: 299-313, 1963.[Abstract/Free Full Text]
  17. Schinkel A. H., Mayer U., Wagenaar E., Mol C. A. A. M., van Deemter L., Smit J. J., van der Valk M. A., Voordouw A. C., Spits H., van Tellingen O., Zijlmans J. M., Fibbe W. E., Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA, 94: 4028-4033, 1997.[Abstract/Free Full Text]
  18. Wijnholds J., Evers R., van Leusden M. R., Mol C. A. A. M., Zaman G. J., Mayer U., Beijnen J. H., van der Valk M., Krimpenfort P., Borst P. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat. Med., 3: 1275-1279, 1997.[Medline]
  19. Hyafil F., Vergely C., Du Vignaud P., Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res., 53: 4595-4602, 1993.[Abstract/Free Full Text]
  20. de Bruin, M., Miyake, K., Litman, T., Robey, R., and Bates, S. E. Reversal of resistance by GF120918 in cell lines expressing the half-transporter MXR. Cancer Lett., in press 1999.



This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
C. E. Garner, E. Solon, C.-M. Lai, J. Lin, G. Luo, K. Jones, J. Duan, C. P. Decicco, T. Maduskuie, S. E. Mercer, et al.
Role of P-Glycoprotein and the Intestine in the Excretion of DPC 333 [(2R)-2-{(3R)-3-Amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide] in Rodents
Drug Metab. Dispos., June 1, 2008; 36(6): 1102 - 1110.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Ose, H. Kusuhara, K. Yamatsugu, M. Kanai, M. Shibasaki, T. Fujita, A. Yamamoto, and Y. Sugiyama
P-glycoprotein Restricts the Penetration of Oseltamivir Across the Blood-Brain Barrier
Drug Metab. Dispos., February 1, 2008; 36(2): 427 - 434.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
I. Kobayashi, K. Saito, T. Moritomo, K. Araki, F. Takizawa, and T. Nakanishi
Characterization and localization of side population (SP) cells in zebrafish kidney hematopoietic tissue
Blood, February 1, 2008; 111(3): 1131 - 1137.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. A. de Vries, J. Zhao, E. Kroon, T. Buckle, J. H. Beijnen, and O. van Tellingen
P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan
Clin. Cancer Res., November 1, 2007; 13(21): 6440 - 6449.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
B. Ebert, A. Seidel, and A. Lampen
Phytochemicals Induce Breast Cancer Resistance Protein in Caco-2 Cells and Enhance the Transport of Benzo[a]pyrene-3-sulfate
Toxicol. Sci., April 1, 2007; 96(2): 227 - 236.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. G. Turner, J. L. Gump, C. Zhang, J. M. Cook, D. Marchion, L. Hazlehurst, P. Munster, M. J. Schell, W. S. Dalton, and D. M. Sullivan
ABCG2 expression, function, and promoter methylation in human multiple myeloma
Blood, December 1, 2006; 108(12): 3881 - 3889.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Zong, S. Zhou, S. Fatima, and B. P. Sorrentino
Expression of Mouse Abcg2 mRNA during Hematopoiesis Is Regulated by Alternative Use of Multiple Leader Exons and Promoters
J. Biol. Chem., October 6, 2006; 281(40): 29625 - 29632.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. A. Seamon, C. A. Rugg, S. Emanuel, A. M. Calcagno, S. V. Ambudkar, S. A. Middleton, J. Butler, V. Borowski, and L. M. Greenberger
Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor.
Mol. Cancer Ther., October 1, 2006; 5(10): 2459 - 2467.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
A Mohan, M Kandalam, H L Ramkumar, L Gopal, and S Krishnakumar
Stem cell markers: ABCG2 and MCM2 expression in retinoblastoma
Br. J. Ophthalmol., July 1, 2006; 90(7): 889 - 893.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Leggas, J. C. Panetta, Y. Zhuang, J. D. Schuetz, B. Johnston, F. Bai, B. Sorrentino, S. Zhou, P. J. Houghton, and C. F. Stewart
Gefitinib Modulates the Function of Multiple ATP-Binding Cassette Transporters In vivo.
Cancer Res., May 1, 2006; 66(9): 4802 - 4807.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K.-i. Nezasa, X. Tian, M. J. Zamek-Gliszczynski, N. J. Patel, T. J. Raub, and K. L. R. Brouwer
ALTERED HEPATOBILIARY DISPOSITION OF 5 (AND 6)-CARBOXY-2',7'-DICHLOROFLUORESCEIN IN Abcg2 (Bcrp1) AND Abcc2 (Mrp2) KNOCKOUT MICE
Drug Metab. Dispos., April 1, 2006; 34(4): 718 - 723.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
C. S. Morrow, C. Peklak-Scott, B. Bishwokarma, T. E. Kute, P. K. Smitherman, and A. J. Townsend
Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediates Resistance to Mitoxantrone via Glutathione-Dependent Drug Efflux
Mol. Pharmacol., April 1, 2006; 69(4): 1499 - 1505.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
K. Meissner, B. Heydrich, G. Jedlitschky, H. Meyer zu Schwabedissen, I. Mosyagin, P. Dazert, L. Eckel, S. Vogelgesang, R. W. Warzok, M. Bohm, et al.
The ATP-binding Cassette Transporter ABCG2 (BCRP), a Marker for Side Population Stem Cells, Is Expressed in Human Heart
J. Histochem. Cytochem., February 1, 2006; 54(2): 215 - 221.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
P. J. Dilda, A. S. Don, K. M. Tanabe, V. J. Higgins, J. D. Allen, I. W. Dawes, and P. J. Hogg
Mechanism of Selectivity of an Angiogenesis Inhibitor From Screening a Genome-Wide Set of Saccharomyces cerevisiae Deletion Strains
J Natl Cancer Inst, October 19, 2005; 97(20): 1539 - 1547.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
X.-f. Zhou, X. Yang, Q. Wang, R. A. Coburn, and M. E. Morris
EFFECTS OF DIHYDROPYRIDINES AND PYRIDINES ON MULTIDRUG RESISTANCE MEDIATED BY BREAST CANCER RESISTANCE PROTEIN: IN VITRO AND IN VIVO STUDIES
Drug Metab. Dispos., August 1, 2005; 33(8): 1220 - 1228.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. D. Norris, J. Smith, K. Tanabe, P. Tobin, C. Flemming, G. L. Scheffer, P. Wielinga, S. L. Cohn, W. B. London, G. M. Marshall, et al.
Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro
Mol. Cancer Ther., April 1, 2005; 4(4): 547 - 553.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. H.G.P. Raaijmakers, E. P.L.M. de Grouw, L. H.H. Heuver, B. A. van der Reijden, J. H. Jansen, R. J. Scheper, G. L. Scheffer, T. J.M. de Witte, and R. A.P. Raymakers
Breast Cancer Resistance Protein in Drug Resistance of Primitive CD34+38- Cells in Acute Myeloid Leukemia
Clin. Cancer Res., March 15, 2005; 11(6): 2436 - 2444.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Zhou, Y. Zong, P. A. Ney, G. Nair, C. F. Stewart, and B. P. Sorrentino
Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels
Blood, March 15, 2005; 105(6): 2571 - 2576.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Zhang, X. Wang, K. Sagawa, and M. E. Morris
FLAVONOIDS CHRYSIN AND BENZOFLAVONE, POTENT BREAST CANCER RESISTANCE PROTEIN INHIBITORS, HAVE NO SIGNIFICANT EFFECT ON TOPOTECAN PHARMACOKINETICS IN RATS OR MDR1A/1B (-/-) MICE
Drug Metab. Dispos., March 1, 2005; 33(3): 341 - 348.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Ozvegy-Laczka, G. Varady, G. Koblos, O. Ujhelly, J. Cervenak, J. D. Schuetz, B. P. Sorrentino, G.-J. Koomen, A. Varadi, K. Nemet, et al.
Function-dependent Conformational Changes of the ABCG2 Multidrug Transporter Modify Its Interaction with a Monoclonal Antibody on the Cell Surface
J. Biol. Chem., February 11, 2005; 280(6): 4219 - 4227.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. Kobayashi, I. Ieiri, T. Hirota, H. Takane, S. Maegawa, J. Kigawa, H. Suzuki, E. Nanba, M. Oshimura, N. Terakawa, et al.
FUNCTIONAL ASSESSMENT OF ABCG2 (BCRP) GENE POLYMORPHISMS TO PROTEIN EXPRESSION IN HUMAN PLACENTA
Drug Metab. Dispos., January 1, 2005; 33(1): 94 - 101.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y.-J. Lee, H. Kusuhara, J. W. Jonker, A. H. Schinkel, and Y. Sugiyama
Investigation of Efflux Transport of Dehydroepiandrosterone Sulfate and Mitoxantrone at the Mouse Blood-Brain Barrier: A Minor Role of Breast Cancer Resistance Protein
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 44 - 52.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. Pavek, G. Merino, E. Wagenaar, E. Bolscher, M. Novotna, J. W. Jonker, and A. H. Schinkel
Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 144 - 152.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P.L. R. Ee, X. He, D. D. Ross, and W. T. Beck
Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference
Mol. Cancer Ther., December 1, 2004; 3(12): 1577 - 1584.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
X. Tian, M. J. Zamek-Gliszczynski, P. Zhang, and K. L. R. Brouwer
Modulation of Multidrug Resistance-Associated Protein 2 (Mrp2) and Mrp3 Expression and Function with Small Interfering RNA in Sandwich-Cultured Rat Hepatocytes
Mol. Pharmacol., October 1, 2004; 66(4): 1004 - 1010.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Yanase, S. Tsukahara, S. Asada, E. Ishikawa, Y. Imai, and Y. Sugimoto
Gefitinib reverses breast cancer resistance protein-mediated drug resistance
Mol. Cancer Ther., September 1, 2004; 3(9): 1119 - 1125.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
T. Furuchi, T. Takahashi, S. Tanaka, K. Nitta, and A. Naganuma
Functions of yeast helicase Ssl2p that are essential for viability are also involved in protection from the toxicity of adriamycin
Nucleic Acids Res., May 11, 2004; 32(8): 2578 - 2585.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Cisternino, C. Mercier, F. Bourasset, F. Roux, and J.-M. Scherrmann
Expression, Up-Regulation, and Transport Activity of the Multidrug-Resistance Protein Abcg2 at the Mouse Blood-Brain Barrier
Cancer Res., May 1, 2004; 64(9): 3296 - 3301.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Nakayama, A. Kanzaki, K. Terada, M. Mutoh, K. Ogawa, T. Sugiyama, S. Takenoshita, K. Itoh, N. Yaegashi, K. Miyazaki, et al.
Prognostic Value of the Cu-Transporting ATPase in Ovarian Carcinoma Patients Receiving Cisplatin-Based Chemotherapy
Clin. Cancer Res., April 15, 2004; 10(8): 2804 - 2811.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Boyer, E. G. McLean, S. Aroori, P. Wilson, A. McCulla, P. D. Carey, D. B. Longley, and P. G. Johnston
Characterization of p53 Wild-Type and Null Isogenic Colorectal Cancer Cell Lines Resistant to 5-Fluorouracil, Oxaliplatin, and Irinotecan
Clin. Cancer Res., March 15, 2004; 10(6): 2158 - 2167.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. L. R. Ee, S. Kamalakaran, D. Tonetti, X. He, D. D. Ross, and W. T. Beck
Identification of a Novel Estrogen Response Element in the Breast Cancer Resistance Protein (ABCG2) Gene
Cancer Res., February 15, 2004; 64(4): 1247 - 1251.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
B. Lassalle, H. Bastos, J. P. Louis, L. Riou, J. Testart, B. Dutrillaux, P. Fouchet, and I. Allemand
`Side Population' cells in adult mouse testis express Bcrp1 gene and are enriched in spermatogonia and germinal stem cells
Development, January 15, 2004; 131(2): 479 - 487.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.